Ascendis Pharma(MX:ASND1N)
MX$4,165.550.00 (0.00%)
MX:ASND1N
Ascendis Pharma earnings date
MX$4,165.55
At close:0.00 (0.00%)
Ascendis Pharma (ASND1N) Q4 2023 Earnings Report
0 Followers
MX:ASND1N Q4 2023 EPS Results
- Actual EPS
- -MXN 31.66
- Consensus EPS
- -MXN 37.31
- Beat/Miss
- Beat by +MXN 5.65
- One Year Ago EPS
- -MXN 76.06
MX:ASND1N Q4 2023 Revenue Results
- Actual Revenue
- MXN 2.75B
- Expected Revenue
- MXN 1.92B
- Beat/Miss
- Beat by +MXN 831.25M
- YoY Revenue Growth
- +534.32%
Earnings Announcement Details
- Quarter
- Q4 2023
- Date
- 02/07/2024
- Time
- After Close
- Conference Call
- Wednesday, February 7, 2024
MX:ASND1N Upcoming Earnings
Ascendis Pharma's next earnings date is estimated for February 17, 2027, based on past reporting schedules.
Q4 2023 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q4 2023 Earnings Slide Deck
No slide deck is available for this earnings event.
Q4 2023 Earnings Call Summary
No earnings call summary is available for this earnings event.
MX:ASND1N Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 17, 2027 | 2026 (Q4) | 31.62- | -11.31 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | 16.2222.20 | -20.56 | 208.00% (+42.76) | |
| Aug 13, 2026 | 2026 (Q2) | 30.7758.17 | -16.86 | 445.12% (+75.03) | |
| May 07, 2026 | 2026 (Q1) | ―200.42 | -32.48 | 717.09% (+232.90) | |
| Feb 11, 2026 | 2025 (Q4) | -1.64-11.31 | -13.16 | 14.06% (+1.85) | |
| Nov 12, 2025 | 2025 (Q3) | -5.02-20.56 | -35.36 | 41.86% (+14.80) | |
| Aug 07, 2025 | 2025 (Q2) | -26.44-16.86 | -39.26 | 57.07% (+22.41) | |
| May 01, 2025 | 2025 (Q1) | -30.16-32.48 | -47.28 | 31.30% (+14.80) | |
| Feb 12, 2025 | 2024 (Q4) | -20.23-13.16 | -31.66 | 58.44% (+18.50) | |
| Nov 14, 2024 | 2024 (Q3) | -32.17-35.36 | -55.3 | 36.06% (+19.94) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
